{
    "CONTRACT_ID": "cb-5228-93665393",
    "type": "C2",
    "department": "Denistry",
    "procurement_category": "SRV",
    "short_summary": "",
    "description": "Manufacting plant for clinical batches of vaccines of different types",
    "estimated_value": 8,
    "date_posted": "15-07-2013",
    "duration_in_months": "From 3 to 18 months",
    "provinces": [
        "Alberta",
        "British Columbia",
        "Manitoba",
        "New Brunswick",
        "Newfoundland and Labrador"
    ],
    "tags": [
        "Manufacting",
        "biomedical",
        "biotechnology",
        "vaccine",
        "plant",
        "chemicals",
        "medicines",
        "rabies",
        "Typhus",
        "infectious disease",
        "Business and Government ",
        "Administrative",
        "Procurement",
        "Sample Collection ",
        "Financial",
        "Environmental",
        "Rendering service",
        "Chemistry",
        "curity",
        "Monitoring",
        "Days",
        "Sampling ",
        "issue",
        "Control",
        "Microbiology Cable PD jointwork ",
        "Cancellation",
        "probable",
        "Delta Equipment fails size",
        "Comparison",
        "Feedback",
        "Importance",
        " translation], "
    ],
    "full_summary": "### Phase 2 - Feasibility Study of Clinical Trial Manufacturing Facility Contract\n\n**Bid Information**\n=====================================\n\n**Title**\n--------\n\n* English: Phase 2 - Feasibility Study of supplemental area Clinical Trial Manufacturing Facility (CTMF)\n* French: Phase 2 - \u00c9tude de faisabilit\u00e9 de la zone suppl\u00e9mentaire d'une Infrastructure de production de mat\u00e9riel pour essais cliniques (IPMEC)\n* Solicitation Number: 23-58010\n* Publication Date: 2023-05-04\n\n**Bidding Details**\n-------------------\n\n* Tender Closing Date: 2023-05-29T14:00:00\n* Expected Contract Start Date: 2023-06-12\n* Expected Contract End Date: 2023-09-30\n* Location: Canada\n\n**Contract Details**\n------------------\n\n* Procurement Category: Service\n* Procurement Method: Competitive - Open bidding\n* Notice Type: Request for Proposal\n* Selection Criteria: Highest Combined Rating of Technical Merit and Price\n\n**Contracting Entity**\n----------------------\n\n* National Research Council (NRC) Canada\n* Address: 1200 Montreal Rd M58, Ottawa, ON K1A 0R6, Canada\n\n**Contact Information**\n-----------------------\n\n* Cindy Romain (Contracting Officer)\n* Email: [cindy.romain@nrc-cnrc.gc.ca](mailto:cindy.romain@nrc-cnrc.gc.ca)\n* Phone: (613) 299-2748\n* Address: 6100 Royalmount Ave, Montreal, QC H4P 2R2, Canada\n\n**Technical Details**\n--------------------\n\n* A feasibility study is required to expand the existing Clinical Trial Manufacturing Facility (CTMF) to meet the growing demand for vaccine production.\n* The project includes the addition of a viral vector ball room, an mNRA vaccine production suite, and a Quality Control Laboratory.\n* The production rooms and utilities will follow the standards of Health Canada Good Manufacturing Practices (GMP), FDA Current Good Manufacturing Practices (cGMP), and Eudralex GMP standards.\n\n**Documentation**\n----------------\n\n* Attachments:\n    * [Appendix A: Phase 2 Feasibility Study SOW Final V2](https://canadabuys.canada.ca/sites/default/files/webform/tender_notice/5228/rfp_23_58010_appendix_a_phase_2_feasibility-study_sow_finalv2_0_0.pdf)\n"
}